DRUG · Unmapped registry intervention
EZN-2208
Find medicine records ·
Find other trials using this name
Clinical trial
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
NCT01036113
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Metastatic Breast Cancerunresolved
Interventions
EZN-2208DRUG
Sponsors & collaborators
Enzon Pharmaceuticals, Inc.lead sponsor
Mapped research locations
DallasTexas, United States4HoustonTexas, United States1ColumbusOhio, United States1PortlandOregon, United States1MinneapolisMinnesota, United States1DenverColorado, United States1AustinTexas, United States1TucsonArizona, United States1Kansas CityMissouri, United States1GreenvilleSouth Carolina, United States1RaleighNorth Carolina, United States1Fort WorthTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01036113 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.